Letters, Testimony & Filings Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee Regarding Lofexidine March 27, 2018
Commentary Outrage of the Month: Opioid Maker Executives “No Better Than Street-Level Drug Dealers” December 1, 2017
Press Releases Trump Declares Opioid Public Health Emergency, But It Will Take More Than Tweets and Big Pharma Nominations to Save Lives October 26, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding A New Extended-Release Oxycodone Product July 26, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding Reformulated Opana ER March 14, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding Extended-Release Morphine Sulfate (Arymo) August 4, 2016
Commentary Outrage of the Month: Congress Finds Money for Big Pharma, but Not Opioid-Addicted Patients August 1, 2016